APLS
Apellis Pharmaceuticals Inc
NASDAQ: APLS · HEALTHCARE · BIOTECHNOLOGY
$40.95
+0.00% today
Updated 2026-04-30
Market cap
$5.24B
P/E ratio
227.50
P/S ratio
5.22x
EPS (TTM)
$0.18
Dividend yield
—
52W range
$16 – $41
Volume
5.5M
Apellis Pharmaceuticals Inc (APLS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-3.44M | $-9.95M | $-18.86M | $-26.00M | $-46.60M | $-131.24M | $-211.13M | $-160.49M | $-563.13M | $-513.75M | $-594.74M | $-87.87M | $45.33M |
| Capital expenditures | $0.00 | $19946.00 | $0.00 | $1.69M | $1.69M | $1.69M | $1.69M | $5.42M | $1.10M | $1.52M | $773000.00 | $403000.00 | $313000.00 |
| Depreciation | $6265.00 | $6594.00 | $11935.00 | $239683.00 | $11935.00 | $239683.00 | $596000.00 | $859000.00 | $1.49M | $1.49M | $1.70M | $1.80M | — |
| Stock-based comp | $271841.00 | $659154.00 | $545701.00 | $1.08M | $5.42M | $7.73M | $21.14M | $45.38M | $70.67M | $91.08M | $105.94M | $114.13M | $104.00M |
| Free cash flow | $-3.44M | $-9.97M | $-18.86M | $-27.70M | $-48.29M | $-132.93M | $-212.83M | $-165.91M | $-564.23M | $-515.27M | $-595.51M | $-88.27M | $45.01M |
| Investing cash flow | — | $-19946.00 | — | $-1.69M | $-1.69M | $-1.69M | $-1.69M | $-316.99M | $247.62M | $59.89M | $-674000.00 | $-403000.00 | — |
| Financing cash flow | $7.16M | $18.83M | $41.24M | $14.86M | $197.38M | $131.90M | $388.54M | $692.18M | $392.24M | $365.66M | $394.50M | $149.24M | — |
| Dividends paid | — | — | — | — | — | — | — | $322.87M | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — |